武田制药Takeda Pharmaceutical（TAK）2024年度综合报告「NYSE」（英文版）（58页）.pdf

1、2024 Annual Integrated Report Fiscal Year Ended March 31,2024 Takeda is a global values-based,research and development(R&D)-driven biopharmaceutical company committed to achievingour corporate purpose:better health for people and a brighter future for the world.Westrive to deliver truly transformati

2、ve treatments,significantly increasing the value that we bring to society.INTRODUCTION A message from our President and Chief Executive Officer A message from our Chief Global Corporate Affairs and Sustainability Officer Takeda at a glance Our foundation for delivering long-term value CORPORATE PHIL

3、OSOPHY Our value creation Corporate philosophy metrics Commitment to the patient Commitment to people Commitment to the planet Unleash the power of data and digital VALUE CREATION A Q&A on sustainable value creation in PDT business A patient-centric approach to drug development Creating positive imp

4、act for health care and climate resilience Easing the burden of Inflammatory Bowel Disease(IBD)70 years of serving community and global needs FINANCIAL PERFORMANCETakedas financial performance fiscal year 2023 APPENDIX Legal disclaimer Financial definitions 2 9 26 49 54 2 CORPORATE PHILOSOPHYVALUE C

5、REATIONFINANCIAL PERFORMANCE APPENDIXTAKEDA 2024 ANNUAL INTEGRATED REPORT INTRODUCTION A message from our President and CEO tetravalent vaccine live,attenuated)and 10 years since the introduction of ENTYVIO(vedolizumab).And we explain how our pipeline has evolved to now include six new molecular ent

6、ities in Phase 3.We also provide examples from our Vienna and Los Angeles sites to illustrate how we can limit our impact on the planet while investing in our manufacturing network.In each section there are stories of how we are accelerating our progress through the use of data,digital and technolog